ITRM20020049A0 - Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. - Google Patents

Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.

Info

Publication number
ITRM20020049A0
ITRM20020049A0 IT2002RM000049A ITRM20020049A ITRM20020049A0 IT RM20020049 A0 ITRM20020049 A0 IT RM20020049A0 IT 2002RM000049 A IT2002RM000049 A IT 2002RM000049A IT RM20020049 A ITRM20020049 A IT RM20020049A IT RM20020049 A0 ITRM20020049 A0 IT RM20020049A0
Authority
IT
Italy
Prior art keywords
glycoprotein
vitro
monoclonal antibody
directed against
human monoclonal
Prior art date
Application number
IT2002RM000049A
Other languages
English (en)
Inventor
Roberto Burioni
Original Assignee
Biostrands S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostrands S R L filed Critical Biostrands S R L
Priority to IT2002RM000049A priority Critical patent/ITRM20020049A1/it
Publication of ITRM20020049A0 publication Critical patent/ITRM20020049A0/it
Priority to DK03705004T priority patent/DK1476468T3/da
Priority to EP03705004A priority patent/EP1476468B9/en
Priority to RU2004126238/13A priority patent/RU2004126238A/ru
Priority to CA2474801A priority patent/CA2474801C/en
Priority to AU2003208000A priority patent/AU2003208000B2/en
Priority to AT03705004T priority patent/ATE407147T1/de
Priority to KR1020047011208A priority patent/KR101002791B1/ko
Priority to ES03705004T priority patent/ES2314179T3/es
Priority to EA200401081A priority patent/EA009861B1/ru
Priority to PCT/IT2003/000032 priority patent/WO2003064473A2/en
Priority to NZ534922A priority patent/NZ534922A/en
Priority to DE60323333T priority patent/DE60323333D1/de
Priority to JP2003564093A priority patent/JP4287280B2/ja
Priority to CNA038030926A priority patent/CN1856508A/zh
Priority to US10/502,307 priority patent/US20050084845A1/en
Publication of ITRM20020049A1 publication Critical patent/ITRM20020049A1/it
Priority to ZA200406187A priority patent/ZA200406187B/en
Priority to US12/128,344 priority patent/US7727529B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IT2002RM000049A 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. ITRM20020049A1 (it)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
US10/502,307 US20050084845A1 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
ES03705004T ES2314179T3 (es) 2002-01-30 2003-01-29 Fragmentos fab de anticuerpo monoclonal humano dirigidos contra la gucoproteina e2 del vhc y que estan dotados de actividad neutralizante in vitro.
PCT/IT2003/000032 WO2003064473A2 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
RU2004126238/13A RU2004126238A (ru) 2002-01-30 2003-01-29 Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
CA2474801A CA2474801C (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
AU2003208000A AU2003208000B2 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
AT03705004T ATE407147T1 (de) 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
KR1020047011208A KR101002791B1 (ko) 2002-01-30 2003-01-29 Ｈｃｖ ｅ2 당단백질을 표적하고 시험관내 중화 활성을보유하는 사람 단클론항체 ｆａｂ 단편
DK03705004T DK1476468T3 (da) 2002-01-30 2003-01-29 Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet
EA200401081A EA009861B1 (ru) 2002-01-30 2003-01-29 Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
EP03705004A EP1476468B9 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
NZ534922A NZ534922A (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
DE60323333T DE60323333D1 (de) 2002-01-30 2003-01-29 Fab-fragmente humaner monoklonaler antikörper mit protein
JP2003564093A JP4287280B2 (ja) 2002-01-30 2003-01-29 ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片
CNA038030926A CN1856508A (zh) 2002-01-30 2003-01-29 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段
ZA200406187A ZA200406187B (en) 2002-01-30 2004-08-03 Human monoclonal antibody fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
US12/128,344 US7727529B2 (en) 2002-01-30 2008-05-28 Human monoclonal antibody Fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.

Publications (2)

Publication Number Publication Date
ITRM20020049A0 true ITRM20020049A0 (it) 2002-01-30
ITRM20020049A1 ITRM20020049A1 (it) 2003-07-30

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.

Country Status (17)

Country Link
US (2) US20050084845A1 (it)
EP (1) EP1476468B9 (it)
JP (1) JP4287280B2 (it)
KR (1) KR101002791B1 (it)
CN (1) CN1856508A (it)
AT (1) ATE407147T1 (it)
AU (1) AU2003208000B2 (it)
CA (1) CA2474801C (it)
DE (1) DE60323333D1 (it)
DK (1) DK1476468T3 (it)
EA (1) EA009861B1 (it)
ES (1) ES2314179T3 (it)
IT (1) ITRM20020049A1 (it)
NZ (1) NZ534922A (it)
RU (1) RU2004126238A (it)
WO (1) WO2003064473A2 (it)
ZA (1) ZA200406187B (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
WO2008107187A1 (en) * 2007-03-06 2008-09-12 Ribovax Biotechnologies S.A. Antibodies specific for rubella virus
CN101809033A (zh) 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
TW200940090A (en) * 2007-12-17 2009-10-01 Medical Res Council Technology Hepatitis C virus antibodies
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ITTO20080964A1 (it) * 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
US9719141B2 (en) 2010-03-01 2017-08-01 Vincent Agnello Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
CN118440202A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
WO2022049867A1 (ja) 2020-09-02 2022-03-10 国立大学法人東京大学 がん免疫微小環境の調節物質およびそれによる予防・診断・治療的利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325517C (zh) * 1998-07-21 2007-07-11 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001273363A1 (en) 2000-07-12 2002-01-21 General Instrument Corporation Method and apparatus for downloading objects via an inband channel with minimal subscriber impact
JP2004524829A (ja) * 2000-12-01 2004-08-19 アメリカ合衆国 Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用

Also Published As

Publication number Publication date
CA2474801A1 (en) 2003-08-07
RU2004126238A (ru) 2005-04-20
ATE407147T1 (de) 2008-09-15
US7727529B2 (en) 2010-06-01
KR101002791B1 (ko) 2010-12-21
EA200401081A1 (ru) 2005-10-27
AU2003208000B2 (en) 2010-05-20
EA009861B1 (ru) 2008-04-28
ES2314179T3 (es) 2009-03-16
CN1856508A (zh) 2006-11-01
EP1476468B1 (en) 2008-09-03
WO2003064473A2 (en) 2003-08-07
JP4287280B2 (ja) 2009-07-01
KR20040077745A (ko) 2004-09-06
EP1476468A2 (en) 2004-11-17
DE60323333D1 (de) 2008-10-16
CA2474801C (en) 2012-03-20
US20050084845A1 (en) 2005-04-21
NZ534922A (en) 2008-07-31
EP1476468B9 (en) 2009-04-08
ITRM20020049A1 (it) 2003-07-30
ZA200406187B (en) 2006-06-28
DK1476468T3 (da) 2009-01-19
WO2003064473A3 (en) 2003-12-24
JP2005531286A (ja) 2005-10-20
US20080241162A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
ITRM20020049A0 (it) Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
CY2019022I2 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
IS7499A (is) Mennsk mótefni gegn beta-amýloíðpeptíðum
IS7668A (is) Manngerð mótefni gegn 4-1BB í mönnum
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
DE60317800D1 (de) Monoklonale antikörper und komplementarität bestimmende regionen mit bindung an ebola glycoprotein
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
NO20034396D0 (no) Rekombinante antistoff uttrykt sammen med GnTIII
IS6982A (is) Mótefni gegn VLA-1
AU2002338015A1 (en) Human CDR-grafted antibodies and antibody fragments thereof
CR7875A (es) Variantes de inmunoglobina y usos de esto
ATE450663T1 (de) Verschleissteil und -anordnung
IL165256A0 (en) Neutralizing human anti-igfr antibody
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
FR17C1053I2 (fr) Remodelage et glycoconjugation de facteur ix
DK1478667T3 (da) Monoklonalt anti-humant tenascin-antistof
HK1096975A1 (en) Monoclonal antibody against influenza b virus and immunoassay instrument using the antibody
AU2003227148A8 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
WO2003106478A3 (en) ANTIBODIES BINDING TO ALPHAE INTEGRIN
ATE513564T1 (de) Immunogener rekombinanter antikörper
FI20021934A0 (fi) Liittopalkki
DE112004002660D2 (de) Humaner monoklonaler Antikörper mit fettsenkender Wirkung
DE50210561D1 (de) Sitz- und/oder liegemöbel
DE502004000756D1 (de) Schalldämpfer sowie Abgasanlage